Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Jason R. Kelly Sells 100,000 Shares of Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Free Report) insider Jason R. Kelly sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $2.13, for a total value of $213,000.00. Following the transaction, the insider now owns 7,094,680 shares of the company’s stock, valued at $15,111,668.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ginkgo Bioworks Stock Performance

DNA opened at $2.08 on Friday. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $1.12 and a 1 year high of $3.52. The stock’s 50 day simple moving average is $2.04 and its 200-day simple moving average is $1.65.

Ginkgo Bioworks (NYSE:DNAGet Free Report) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). The business had revenue of $80.57 million for the quarter, compared to analysts’ expectations of $70.41 million. Ginkgo Bioworks had a negative return on equity of 66.58% and a negative net margin of 375.48%. As a group, equities analysts expect that Ginkgo Bioworks Holdings, Inc. will post -0.35 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on DNA shares. Raymond James cut their price target on Ginkgo Bioworks from $5.00 to $3.50 and set an “outperform” rating for the company in a report on Thursday, August 31st. The Goldman Sachs Group lowered Ginkgo Bioworks from a “neutral” rating to a “sell” rating and cut their price target for the stock from $3.00 to $1.25 in a report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Based on data from, the stock has an average rating of “Hold” and an average target price of $3.75.

Read Our Latest Report on DNA

Institutional Trading of Ginkgo Bioworks

A number of institutional investors and hedge funds have recently modified their holdings of the company. Yousif Capital Management LLC bought a new stake in Ginkgo Bioworks in the second quarter valued at $25,000. Creative Planning bought a new stake in Ginkgo Bioworks in the fourth quarter valued at $25,000. Silverlake Wealth Management LLC bought a new stake in Ginkgo Bioworks in the fourth quarter valued at $25,000. Private Advisor Group LLC bought a new stake in Ginkgo Bioworks in the first quarter valued at $26,000. Finally, Endurance Wealth Management Inc. grew its position in Ginkgo Bioworks by 100.0% in the first quarter. Endurance Wealth Management Inc. now owns 20,000 shares of the company’s stock valued at $27,000 after acquiring an additional 10,000 shares during the period. 56.84% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Company Profile

(Get Free Report)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Featured Articles

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with's FREE daily email newsletter.